Hume Kyle - Sumitomo Dainippon Insider

Sumitomo Dainippon Pharma Co Ltd -- Germany Stock  

EUR 11.98  0.14  1.18%

CFO, Executive Vice President

Mr. Hume D. Kyle is a Chief Financial Officer and Executive Vice President of Dundee Precious Metals Inc., with effective from June 6, 2011. Mr. Kyle has more than 25 years of experience as a financial executive in a number of complex, publicly traded, multinational energy and natural resource businesses. He has held a range of increasingly senior roles in public practice and private industry including Assistant Treasurer, Treasurer Vice President, Finance and Controller, and Chief Financial Officer. Most recently, Mr. Kyle served as Vice President, Treasurer and Controller, of TransAlta Corporationrationration, an 11 billion power generating company where he was responsible for providing leadership over the financial activities of the organization, principally in the areas of corporate accounting and reporting, strategic finance, treasury, taxation, and financial systems, processes and controls
  President Since 2011      
Kyle holds a Bachelor of Arts degree in Economics and Accounting from the University of Western Ontario and a Graduate Diploma in Public Accounting from McGill University. He is also a Chartered Accountant and a Chartered Financial Analyst.

Management Efficiency

The company has return on total asset (ROA) of 4.94 % which means that it generated profit of $4.94 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 7.8 % meaning that it generated $7.8 on every $100 dollars invested by stockholders.
The company has accumulated 599.08 M in total debt with debt to equity ratio (D/E) of 14.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sumitomo Dainippon Pharma Co Ltd has Current Ratio of 1.66 which is within standard range for the sector.

Similar Executives

Entity Summary

Sumitomo Dainippon Pharma Co Ltd (DPM) is traded on Frankfurt Stock Exchange in Germany. and employs 26 people.

Did you try this?

Run Idea Analyzer Now
   

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Hide  View All  NextLaunch Idea Analyzer
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Sumitomo Dainippon Pharma Co Ltd to your portfolio

Top Management

Sumitomo Dainippon P Leadership Team
Peter Nixon, Director
Richard Gosse, President
Colin McAnuff, Executive
W John, Director, MBA
Richard Howes, President
Garth MacRae, Director
Zebra Kasete, President, MBA
Donald Young, Director
Lori Beak, President
Jeremy Kinsman, Director, MBA
Brent Johnson, President
Paul Proulx, President
Nikolay Hristov, President
Derek Buntain, Director, MBA
Hratch Jabrayan, President
Jonathan Goodman, CEO, MBA
John Lindsay, President
Mark Crawley, President
Peter Gillin, Director
MarieAnne Tawil, Director, MBA
Hume Kyle, President
Anthony Walsh, Director
Juanita Montalvo, Director
David Rae, President
Michael Dorfman, President
Murray John, Director, MBA
R Gillin, Director

Stock Performance

Sumitomo Dainippon Performance Indicators